Controlled clinical trial of interferon-γ as postoperative surgical adjuvant therapy for colon cancer

Abstract

Purpose: The primary goal of this study was to assess the effectiveness of interferon gamma (IFN-γ) to prevent tumor relapse following potentially curative surgery in patients with high-risk colon cancer. A secondary goal was to determine the effect of IFN-γ on immune function and to correlate alterations in immune parameters with survival. Patients and Methods: Three to 4 weeks after undergoing resection of all known malignant disease, 99 patients with stage II, III, or IV colon cancer were randomly assigned to receive IFN-γ, 0.2 mg total dose by subcutaneous injection daily for 6 months or observation. Serial assessment of human leukocyte antigen (HLA)-DR expression and Fc receptors on peripheral-blood monocytes was conducted in 24 patients who received IFN-γ and 27 control patients. Results: With a median follow-up duration of 59 months in patients still alive, there was evidence of a detrimental effect on time to relapse (P = .03) among patients who received IFN-γ. There was no significant difference in patient survival (P = .12). This study has sufficient power to rule out a 25% reduction in death rate for patients who received IFN-γ IP < .05). Significant enhancement of immune function was observed in patients treated with IFN-γ as measured by HLA-DR expression (P < .01) and Fc receptors (P < .001) on peripheral-blood monocytes. Conclusion: This study effectively rules out any clinically meaningful benefit for IFN-γ as surgical adjuvant treatment for patients with high-risk colon cancer. Although significant enhancement of nonspecific immune function was seen with this dosage administration schedule of IFN-γ, this was not associated with any demonstrable antitumor effect.